Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.53 USD | -0.09% | +4.34% | +33.14% |
Apr. 19 | Lake Street Starts Cellebrite DI With Buy Rating, $13 Price Target | MT |
Apr. 01 | BofA Securities Adjusts Cellebrite DI Price Target to $13 From $12, Maintains Buy Rating | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 61% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 72.4 and 48.53 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Sector: Software
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+33.14% | 2.37B | - | ||
+11.75% | 3,123B | C+ | ||
+10.06% | 86.45B | B | ||
+6.04% | 78.6B | B+ | ||
-14.66% | 53.98B | B+ | ||
+26.73% | 48.46B | D+ | ||
-24.44% | 46.78B | B- | ||
+31.74% | 46.36B | D+ | ||
+82.12% | 42.36B | D+ | ||
-8.15% | 25.25B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CLBT Stock
- Ratings Cellebrite DI Ltd.